| Frances Dernbach, MD | |
|
925 Stevens Dr, Ste. 3a, Richland, WA 99352-3523 | |
| (509) 946-6565 | |
| (509) 946-0998 |
| Full Name | Frances Dernbach |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 925 Stevens Dr, Richland, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184702862 | NPI | - | NPPES |
| 1084888 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD00031280 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Frances Dernbach, MD 925 Stevens Dr, Ste 3a, Richland, WA 99352 Ph: (509) 946-6565 | Frances Dernbach, MD 925 Stevens Dr, Ste. 3a, Richland, WA 99352-3523 Ph: (509) 946-6565 |
News Archive
As incredible as it sounds, a rice paddy field could one day yield an inexpensive way to prevent HIV.
A new study published in the preprint journal medRxiv in April 2020 explores the possibilities of launching smaller waves of voluntary social exposure in a controlled way, to avoid the occurrence of a single large and probably unmanageable second wave of infection.
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.
In an effort to mitigate the spread of COVID-19 and to optimize allocation of healthcare resources, researchers are improving ways to treat patients with acute large vessel occlusion strokes in a safe manner that also better protects health care workers.
› Verified 6 days ago
Phat P Pham, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 112 Columbia Point Dr Ste 103, Richland, WA 99352 Phone: 509-747-6707 | |
Nitish Jagpal, Pediatrics Medicare: Medicare Enrolled Practice Location: 829 Goethals Dr, Richland, WA 99352 Phone: 509-547-2204 Fax: 509-542-8836 | |
Stephanie M Charron, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1135 Jadwick Ave, Richland, WA 99352 Phone: 509-942-3300 Fax: 509-946-1868 | |
Dr. Santhosh Theyyil Somashekar, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-946-4611 Fax: 509-942-2185 | |
Dr. Ronald Henry Wojnas, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1445 Spaulding Ave, Richland, WA 99352 Phone: 509-420-0423 | |
Dr. Gerald Charles Frey, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 355 Rockwood Drive, Richland, WA 99352 Phone: 509-628-3961 |